A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy

Exclusion Criteria

• •1. Subjects who have active hepatic, small intestine, or biliary tract disease.
• •2. Subjects who have active ulcerative colitis, Crohn's disease, other inflammatory bowel disease.
• •3. Subjects with known malignancy requiring treatment \< 6 months prior to study screening.
• •4. Subjects who have, in the opinion of the investigator, significant concurrent medical illness.
• •5. Subjects who are currently taking concomitant medications which may interfere with study evaluation.
• •6. Subjects who have received an investigational drug within 30 days or within a time period consistent with a washout period of 5 half-lives, whichever is longer, of the first dose of ceftriaxone.
• •7. Subjects with a known history of allergy to any cephalosporin, penicillin or any β-lactam antibiotic.
• •8. Subjects who have known active malabsorption syndromes(s) that, in the judgment of the investigator, could compromise the objectives of the study.
• •9. Subjects who have used any oral, intramuscular, or IV anti-microbial medication during the last 3 weeks prior to the screening visit.